Dosing and infusion rates

Privigen is a ready-to-use 10% liquid intravenous immunoglobulin (IVIg) with no warming or reconstitution necessary. It should be given by a separate infusion line and not mixed with other intravenous medications.* See the chart below or use the dosing calculator to find the recommended dosage for your patient.
*Privigen may be diluted with dextrose injection, USP (D5W).

PI
CIDP
Chronic ITP

Recommended dosing and infusion rates for PI

Dose 200–800 mg/kg (2–8 mL/kg) every 3–4 weeks
Initial infusion rate 0.5 mg/kg/min (0.005 mL/kg/min)
Maximum infusion rate (if tolerated) Increase to 8 mg/kg/min (0.08 mL/kg/min)
Dose Initial infusion rate Maximum infusion rate (if tolerated)
200–800 mg/kg (2–8 mL/kg) every 3–4 weeks 0.5 mg/kg/min (0.005 mL/kg/min) Increase to 8 mg/kg/min (0.08 mL/kg/min)

Monitor the patient’s vital signs throughout the infusion. Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient.

Recommended dosing and infusion rates for chronic ITP

Dose 1 g/kg (10 mL/kg) daily for 2 consecutive days
Initial infusion rate 0.5 mg/kg/min (0.005 mL/kg/min)
Maximum infusion rate (if tolerated) Increase to 4 mg/kg/min (0.04 mL/kg/min)
Dose Initial infusion rate Maximum infusion rate (if tolerated)
1 g/kg (10 mL/kg) daily for 2 consecutive days 0.5 mg/kg/min (0.005 mL/kg/min) Increase to 4 mg/kg/min (0.04 mL/kg/min)

Monitor the patient’s vital signs throughout the infusion. Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient.

Recommended dosing and infusion rates for CIDP

Loading dose 2 g/kg (20 mL/kg) in divided doses over 2 to 5 consecutive days
Maintenance dose
1 g/kg (10 mL/kg) administered in 1 to 2 infusions on consecutive days, every 3 weeks
Initial infusion rate 0.5 mg/kg/min (0.005 mL/kg/min)
Maximum infusion rate (if tolerated) Increase to 8 mg/kg/min (0.08 mL/kg/min)
Loading dose Maintenance dose Initial infusion rate Maximum infusion rate (if tolerated)

2 g/kg (20 mL/kg) in divided doses over 2 to 5 consecutive days
1 g/kg (10 mL/kg) administered in 1 to 2 infusions on consecutive days, every 3 weeks 0.5 mg/kg/min (0.005 mL/kg/min) Increase to 8 mg/kg/min (0.08 mL/kg/min)

Monitor the patient’s vital signs throughout the infusion. Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient.

Dosing calculator

Dosing Calculator Step 1 Patient Profile

 

Loading dose: 2 g/kg (20 mL/kg) in divided doses over 2 to 5 consecutive days
Maintenance dose: 1 g/kg (10 mL/kg) administered in 1 to 2 infusions on consecutive days, every 3 weeks
ITP Dose: 1 g/kg (10 mL/kg) daily for 2 consecutive days
PI Dose: 200–800 mg/kg (2–8 mL/kg) every 3–4 weeks
Dosing Calculator Step 2 Infusion Rate
0.3
min
2.4
max
4.8
max
4.8
max
2.4 mL/kg/h
Initial 0.5 mg/kg/min
(0.005 mL/kg/min)
Maintenance
(as tolerated)
Increase to 4 mg/kg/min
(0.04 mL/kg/min)
Initial 0.5 mg/kg/min
(0.005 mL/kg/min)
Maintenance
(as tolerated)
Increase to 8 mg/kg/min
(0.08 mL/kg/min)
Initial 0.5 mg/kg/min
(0.005 mL/kg/min)
Maintenance
(as tolerated)
Increase to 8 mg/kg/min
(0.08 mL/kg/min)
For patients at risk for renal dysfunction or thrombosis or patients switching from another Ig product, always start at the minimum dose and infusion rate.
Back
Dosing Calculator Step 3 Calculated
Infusion Rate
000 mL/h
Total Dose: mL
Total Infusion Time:
  • Monitor the patient’s vital signs throughout the infusion
  • Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient
  • Titrate based on patient tolerability
Back
  • Calculate each daily dose by dividing the total loading dose above by the number of consecutive infusion days (2, 3, 4, or 5).
  • Assess corresponding infusion time by dividing by the number of consecutive infusion days.
  • If you choose to administer the maintenance dose over 2 consecutive days, divide the total dose above by 2 and administer that amount each day.
  • Assess corresponding infusion time by dividing by the number of consecutive infusion days.

Please consult the prescribing information for complete dosing and infusion information.

Maintenance therapy in CIDP has not been studied for periods longer than 6 months. Individualize duration of treatment beyond 6 months based on patient responses.

Download a PDF of dosing and infusion rates based on patient weight or use the calculator above to find precise dosing information for each patient.

Download the Privigen infusion rates brochure

Order Privigen now

To order, please contact your GPO or distributor. Privigen is available in these four convenient vial sizes:

Privigen vial size 50 mL
Grams 5
Fill Size (mL) 50
NDC Number 44206-436-05
Privigen vial size 100 mL
Grams 10
Fill Size (mL) 100
NDC Number 44206-437-10
Privigen vial size 200 mL
Grams 20
Fill Size (mL) 200
NDC Number 44206-438-20
Privigen vial size 400 mL
Grams 40
Fill Size (mL) 400
NDC Number 44206-439-40
IgIQ

IgIQ: Get information regarding ordering, billing, coding, and reimbursement

IgIQ can help. It’s your single source for Ig solutions from CSL Behring. Find out more or call 877-355-4447 to speak with an expert.

Starting new patients on Privigen

When starting new patients on Privigen therapy:

  • Start at a slow rate of infusion and gradually increase as tolerated
  • Privigen should be administered at the minimum dose and infusion rate practicable in patients judged to be at risk of renal failure, renal dysfunction, or thrombotic events
  • Patients at risk of thrombosis, renal dysfunction, or renal failure should not be volume depleted when initiating intravenous immunoglobulin (IVIg) therapy. Ensure adequate hydration before administering Privigen
  • The patient's vital signs should be monitored carefully throughout the infusion for adverse reactions
  • If adverse reactions occur, the infusion should be stopped or slowed down until the symptoms subside, and may be resumed at a more comfortable, lower rate

Transitioning patients from another Ig product to Privigen

If you are transitioning patients from another Ig product to Privigen:

  • Always start at the minimum rate of infusion
  • The patient's vital signs should be monitored carefully throughout the infusion for adverse reactions
  • If adverse reactions occur, the infusion should be stopped or slowed down until the symptoms subside, and may be resumed at a more comfortable, lower rate
  • Titrate based on patient tolerability

Monitoring patients for adverse reactions

Patients receiving Privigen should be observed and monitored carefully throughout the infusion. If adverse reactions occur, the infusion should be slowed or stopped until the symptoms subside. The infusion may then be resumed at a lower rate that is comfortable for the patient. Following are some other things to keep in mind:

  • Thrombosis Warning

    Thrombosis may occur with immune globulin products, including Privigen. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors

  • Renal Failure Warning

Renal dysfunction, acute renal failure, osmotic nephrosis, and death may be associated with the administration of Immune Globulin Intravenous (Human) (IVIg) products in predisposed patients. Administer IVIg products at the minimum dose and infusion rate possible. Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIg products containing sucrose. Privigen does not contain sucrose.

  • Therapy Contraindications

Privigen is contraindicated in patients with history of anaphylactic or severe systemic reaction to human immune globulin, in patients with hyperprolinemia, and in IgA-deficient patients with antibodies to IgA and history of hypersensitivity.

  • Warnings and Precautions
    • Immunoglobulin A (IgA)-deficient patients with antibodies to IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions
    • Privigen contains a trace amount of IgA (≤25 mcg/mL)
    • Monitor renal function, including blood urea nitrogen and serum creatinine before the initial infusion of Privigen, and urine output in patients at risk of developing acute renal failure
    • Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IVIg therapy
    • Thrombotic events may occur. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for those at risk for hyperviscosity. Thrombosis may occur in the absence of known risk factors
    • Aseptic meningitis syndrome (AMS) may occur, especially with high doses and/or rapid infusion. AMS usually begins within several hours to 2 days following IVIg treatment
    • Hemolysis can develop subsequent to Privigen treatments due to enhanced red blood cell sequestration. Monitor patients for hemolysis and hemolytic anemia
    • Elevations of systolic and/or diastolic blood pressure (including cases of hypertensive urgency) have been observed during/shortly following Privigen infusion. These blood pressure elevations were resolved or significantly improved within hours with either observation alone or changes in oral anti-hypertensive therapy. Check patients for a history of hypertension and/or current use of antihypertensive medication and monitor blood pressure prior, during, and following Privigen infusion
    • Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). Symptoms typically appear within 1 to 6 hours following treatment
    • Carefully consider the relative risks and benefits before prescribing the high dose regimen (for chronic ITP and CIDP) in patients at increased risk of thrombosis, hemolysis, acute kidney injury, or volume overload
    • Privigen is made from human blood and may contain infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease agent and, theoretically, the Creutzfeldt-Jakob disease agent
    • Various passively transferred antibodies in immunoglobulin preparations may lead to misinterpretation of the results of serological testing

Please see Important Safety Information and full prescribing information.

You are now leaving the current website.

Do you want to continue?